// App-Quantinova.ai

422 : An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts

Researchers

Presenter

  • Mark Middleton

Principal Investigators

  • Joseph Sacco

  • Mohammed Milhem

  • Brendan Curti

  • Ari VanderWalde MBioeth

  • Scott Baum

  • Adel Samson

  • Anna Pavlick

  • Jason Chesney

  • Jiaxin Niu

  • Terence Rhodes

  • Tawnya Bowles

  • Robert Conry

  • Anna Olsson-Brown

  • Douglas Earl Laux

  • Howard Kaufman

  • Praveen Bommareddy

  • Alex Deterding

  • Selda Samakoglu

  • Robert Coffin

  • Kevin Harrington

Medical Centers

  • OCDEM, University of Oxford, Oxford, UK

  • University of Liverpool, Liverpool, UK

  • Providence Cancer Center, Portland, OR

  • West Cancer Center, Germantown, TN

  • University of Leeds, Leeds, UK

  • Laura and Isaac Perlmutter Cancer Center, New York, NY.

  • James Graham Brown Cancer Ctr, Louisville, KY

  • Banner MD Anderson Cancer Center, Goodyear, AZ, USA

  • Intermountain Med Center, St. George, UT, USA

  • Intermountain Medical Center, Murray, UT, USA

  • University of Alabama, Birmingham, AL

  • Massachusetts General Hospital, Boston, MA

  • Replimune, Inc., Woburn, MA

  • The Institute of Cancer Research, London, UK

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Skin carcinoma

  • Melanoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved